Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Oramed Pharmaceuticals and Dianthus Therapeutics, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Oramed Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
Dianthus Therapeutics | 0 | 0 | 8 | 2 | 3.20 |
Dianthus Therapeutics has a consensus target price of $44.71, suggesting a potential upside of 65.67%. Given Dianthus Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Dianthus Therapeutics is more favorable than Oramed Pharmaceuticals.
Insider and Institutional Ownership
Earnings & Valuation
This table compares Oramed Pharmaceuticals and Dianthus Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Oramed Pharmaceuticals | $1.34 million | 72.77 | $5.53 million | $0.26 | 9.23 |
Dianthus Therapeutics | $4.12 million | 196.63 | -$43.56 million | ($5.83) | -4.73 |
Oramed Pharmaceuticals has higher earnings, but lower revenue than Dianthus Therapeutics. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Oramed Pharmaceuticals and Dianthus Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Oramed Pharmaceuticals | N/A | 2.70% | 2.10% |
Dianthus Therapeutics | -1,376.42% | -21.03% | -20.18% |
Risk & Volatility
Oramed Pharmaceuticals has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.
Summary
Dianthus Therapeutics beats Oramed Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.